AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET Company Participants James C. Clemmer - CEO, President & Director Stephen A.
AngioDynamics (ANGO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.06 per share a year ago.
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
1 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
15 Jul 2025 Date | | - Cons. EPS | - EPS |
9 Jul 2025 Date | | - Cons. EPS | - EPS |
2 Apr 2025 Date | | - Cons. EPS | - EPS |
2 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
1 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
15 Jul 2025 Date | | - Cons. EPS | - EPS |
9 Jul 2025 Date | | - Cons. EPS | - EPS |
2 Apr 2025 Date | | - Cons. EPS | - EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | James C. Clemmer CEO | NASDAQ (NGS) Exchange | 03475V101 Cusip |
US Country | 748 Employees | - Last Dividend | - Last Split | 27 May 2004 IPO Date |
AngioDynamics, Inc. is a prominent provider of invasive medical devices, catering to the needs of professional healthcare providers across the United States and internationally. The company specializes in a broad spectrum of medical areas, including vascular access, surgery, peripheral vascular disease, and oncology. Established in 1988, AngioDynamics is committed to enhancing patient outcomes through its innovative technologies and solutions, headquartered in Latham, New York.